Source: Healio News
Patients with multiple myeloma mounted suboptimal and variable antibody responses to the messenger RNA COVID-19 vaccines, according to study results published in Cancer Cell.
Additionally, patients who had not contracted COVID-19 before messenger RNA (mRNA) vaccination were more likely to have delayed and suboptimal vaccine responses, and those on active cancer treatment had significantly lower antibody levels after both vaccine doses.
“COVID-19 vaccines are highly effective in preventing severe infections or death, but patients with multiple myeloma are immunocompromised and often on